多发性骨髓瘤感染风险升高的免疫生物标志物
该研究对1786例不同疾病阶段和治疗场景的多发性骨髓瘤患者进行骨髓和外周血二代流式免疫分析,发现发生感染的患者骨髓中CD27+ B细胞和CD27-自然杀伤细胞比例显著降低,CD27-/CD27+ T细胞比值升高。基于这些风险因素构建的免疫评分可区分感染风险,评分≥2个风险因素者感染发生率显著更高(60% vs 35%,P< .001)。免疫评分、疾病分期及靶向CD38、BCMA或GPRC5D的治疗均与感染发生率独立相关。
要点
- 骨髓CD27+ B细胞和CD27- NK细胞比例降低、CD27-/CD27+ T细胞比值升高与感染风险增加相关。
- 免疫评分≥2个风险因素者感染发生率60%,≤1个者为35%(P< .001)。
- 免疫评分、疾病分期及CD38/BCMA/GPRC5D靶向治疗为感染发生的独立相关因素。
核心结论
- 骨髓免疫表型特征可反映多发性骨髓瘤患者感染风险升高,免疫评分有助于风险分层。
研究设计与样本
- 研究采用二代流式细胞术对1786例不同疾病阶段和治疗场景的多发性骨髓瘤患者进行骨髓和外周血免疫分析。
主要发现
- 发生感染的患者骨髓中CD27+ B细胞和CD27-自然杀伤细胞百分比显著降低,CD27-/CD27+ T细胞比值升高。
- 上述免疫风险因素在3个独立数据集中得到验证。
- 免疫评分≤1 vs ≥2个风险因素者感染发生率分别为35% vs 60%(P< .001)。
- 免疫评分(比值比2.31;P< .001)、疾病分期及CD38、BCMA或GPRC5D靶向治疗与感染发生率独立相关。
- 骨髓与外周血中所有可检测细胞类型显著相关,提示可通过微创方法监测免疫生物标志物。
关键数值与推荐
- 免疫评分基于骨髓CD27+ B细胞百分比、CD27-自然杀伤细胞百分比及CD27-/CD27+ T细胞比值三项风险因素。
- 免疫评分≤1 vs ≥2个风险因素对应的感染发生率为35% vs 60%(P< .001)。
- 免疫评分与感染发生的比值比为2.31(P< .001)。
临床怎么用
- 可利用常规实验室可及的微创外周血免疫表型监测多发性骨髓瘤患者的感染风险。
- 对免疫评分≥2个风险因素者,尤其是接受CD38、BCMA或GPRC5D靶向治疗者,应加强感染预防。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Infection remains a leading cause of morbidity in multiple myeloma. Preventing infections is paramount and immune profiling could reflect the cumulative effect of host-, tumor-, and treatment-related immunosuppression. However, current understanding of immune dysfunction and its association with infection is limited. To address this gap in knowledge and identify immune biomarkers of increased infection risk, we performed immune profiling using next-generation flow cytometry in bone marrow and peripheral blood samples from 1786 patients at various disease stages and treatment scenarios. Patients developing infection had significantly lower percentages of CD27+ B cells and CD27- natural killer cells, as well as an increased CD27-/CD27+ T-cell ratio in the bone marrow. These immune risk factors were validated in 3 independent data sets. An immune score was developed to stratify patients with ≤1 vs ≥2 of the aforementioned risk factors, which was associated with higher infection incidence (35% vs 60%, P< .001). The immune score (odds ratio, 2.31; P< .001), disease stage, and CD38-, B-cell maturation antigen-, or G protein-coupled receptor class C group 5 member D-targeted therapy were independently associated with infection incidence. All cell types detectable in the bone marrow and peripheral blood were significantly correlated, suggesting that immune biomarkers of increased infection risk could be monitored using minimally invasive methods that are available in routine laboratories.
引用
- Zabaleta A, Tamariz-Amador LE, Kostopoulos IV, et al. Immune biomarkers of increased infection risk in multiple myeloma. Blood. 2026. PMID: 41610428. doi:10.1182/blood.2025031744
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。